Clinical trials: Omeprazole, completed
Healthy
A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults.
- Trial name
- NCT02638116
- Testing
- Ibrutinib, Omeprazole
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Erosive Esophagitis
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
- Trial name
- NCT01499368
- Testing
- Lafutidine, Famotidine, Omeprazole
- Volunteers
- 495 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy Volunteers
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.
- Trial name
- NCT05134350
- Testing
- LOXO-305, Omeprazole
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Healthy Participants
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.
- Trial name
- NCT05599828
- Testing
- AMG 510, Omeprazole, Famotidine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
COVID-19
Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19
This retrospective cohort study aims to evaluate the effect of proton pump inhibitor (PPI) or histamine-2 receptor antagonist (H2RA) on the clinical outcomes and positivity rates of Coronavirus Disease-19 (COVID-19).
- Trial name
- NCT04834752
- Testing
- No intervention (Retrospective Cohort Observational)
- Where
- South Korea
- Volunteers
- 400,000 people
- Sponsor
- Seoul National University Hospital
Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are…
- Trial name
- NCT05981365
- Testing
- Voxelotor, Bupropion, Repaglinide
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pharmacokinetic Study
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
This is a single-center, open-label, fixed sequence phase I clinical study. To evaluate the effect of continuous administration of omeprazole magnesium enteric coated tablets on PK after single dose AB-106 capsule administration…
- Trial name
- NCT05609929
- Testing
- Multiple administration of omeprazole Single administration of AB-106
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Healthy
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants.
- Trial name
- NCT05338502
- Testing
- Selpercatinib, Ranitidine, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Healthy
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
This study is aimed to investigate the influence of cenobamate on the activity of CYP3A4/5, CYP2B6, CYP2C19, and CYP2C9 by using drugs recommended by both the FDA and EMA as in vivo probes.
- Trial name
- NCT03234699
- Testing
- Cenobamate, midazolam, Warfarin Pill
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- SK Life Science, Inc.
Clostridium Difficile
Effects of Gastric Acid on Colonic Microbiome
The colonic microbiome is essential in human health and disease. Clostridium difficile-associated diarrhea (CDAD), a highly morbid form of infectious diarrhea, is caused by antibiotics which perturb the microbiome and allow C.
- Trial name
- NCT01901276
- Testing
- Omeprazole 40 mg bid
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Daniel Freedberg, MD
Rheumatoid Arthritis
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
- Trial name
- NCT04246762
- Testing
- Olokizumab, Omeprazole, Caffeine
- Where
- 2 sites in Bulgaria, Moldova
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Healthy Participants
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
This is a Phase 1, open-label, multiple dose, single fixed-sequence, 2-period study to evaluate the effect of abrocitinib on the pharmacokinetics (PK) of caffeine, efavirenz and omeprazole in healthy adult participants.
- Trial name
- NCT05067439
- Testing
- Abrocitinib, Omeprazole, Caffeine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alcohol Withdrawal
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
The aim of this study is to elucidate if CYP-phenotypes, variations in CYP-genotypes and dose of chlordiazepoxide is correlated to chlordiazepoxide plasma concentrations in patients admitted to Intensive Care or High Dependency…
- Trial name
- NCT05563350
- Testing
- Blood samples
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Pancreatic Insufficiency, Cystic Fibrosis
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency.
- Trial name
- NCT03551691
- Testing
- Omeprazole 20mg Capsule
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospital of Philadelphia
Drug Drug Interaction
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam, Omeprazole, Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of…
- Trial name
- NCT06031454
- Testing
- Midazolam, Omeprazole, Rosuvastatin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
With high NNTs for indiscriminative use in chronic pain, treatment unavoidably entails frustrating long trial and errors. It is timely to identify biomarkers that can predict analgesic efficacy for the individual patient.
- Trial name
- NCT05256342
- Testing
- Duloxetine 60mg, Etoricoxib 60 mg, omeprazol
- Where
- 2 sites in Israel
- Volunteers
- 17 people
- Sponsor
- Rambam Health Care Campus
Pain
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
The purpose of this study is to evaluate the pharmacokinetics and safety of VX-548 and its metabolite in the absence and presence of omeprazole or rifampin, in healthy participants.
- Trial name
- NCT05635110
- Testing
- VX-548, Omeprazole, Rifampin
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
H.Pylori Infection
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
Our study aimed to investigate the efficacy and safety of hybrid regimen as a first line therapy for H. pylori eradication compared to triple and quadruple regimens in attempt to overcome antibiotic resistance
- Trial name
- NCT06315478
- Testing
- Omeprazole 20 MG Oral Tablet, Amoxicillin 500Mg Tab, Clarithromycin 500Mg Tab
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Helwan University
Metabolism of Clopidogrel
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug.
- Trial name
- PGXB2B (NCT01341600)
- Testing
- Clopidogrel, Omeprazole/Clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore